

## Dr. Michael McKenzie, MD - Publications

1. McKenzie MR, Souhami L, Podgorsak EB, Olivier A, Caron J L, Villemure J G: Photon radiosurgery: A clinical review. *Can J Neurosciences* 1992 (May); 19(2):212-221.
2. McKenzie MR, Freeman CR, Pla M, Guerra J, Souhami L, Podgorsak EB: Clinical experience with electron pseudoarc therapy. *Brit J Radiol* 1993 (March); 66(783):234-240.
3. McKenzie MR, Wong FLW, Epstein JLB, Lepawsky ML: Hyperbaric oxygen and post radiation osteonecrosis of the mandible. *Oral Oncol, Europ J Cancer* 1993 (July); 29B(3):201-207.
4. McKenzie MR, Souhami L, Caron J-L, Olivier A, Villemure J-G, Podgorsak EB: Early and late complications following dynamic stereotactic radiosurgery and fractionated stereotactic radiotherapy. *Can J Neurol Sci* 1993(Nov); 20(4):279-285.
5. Leong C, McKenzie MR, Coupland DB, Gascoyne RD: Disseminated intravascular coagulation in a patient with metastatic prostate cancer: Fatal outcome following strontium-89 therapy. *J Nuclear Med* 1994 (Oct); 35(10):1662-1664.
6. Wong E, Lam S, Grafton C, Wong F, Morris W, McKenzie M, Goddard K, Yuen K: HDR brachytherapy for obstructive bronchial tumors. *J Bronchol* 1994;1(2):99-104.
7. Epstein J, van der Meij E, McKenzie M, Wong F, Lepawsky, Stevenson-Moore P: Postradiation osteonecrosis of the mandible: A long-term follow-up study. *Oral Surg Oral Pathol Oral Radiol Endodont* 1997 (Jun);83(6):657-662.
8. McLaren D, McKenzie M, Duncan G, Pickles T: Watchful waiting or watchful progression? Prostate specific antigen doubling times and clinical behaviour in early untreated prostate cancer. *Cancer* 1998 (Jan);82(2):342-348.
10. Westeel V, Murray N, Gelmon K, Shah A, Sheehan F, McKenzie, Wong F, Morris J, Grafton C, Tsang, V, Goddard K, Murphy K, Parsons C, Amy R, Page R: New combination of the old drugs for elderly patients with small-cell lung cancer: A Phase II study of the PAVE regimen. *J Clin Oncol* 1998 (May);16(5):1940-1947.
11. McKenzie MR: Palliative care and oncology: Linking the two solitudes. *Can Med Ass J* 1998 (Jun);158(13):1702-1704.
12. Pickles T, Goodman GB, Fryer CJ, Bowen J, Coldman A, Duncan GG, Graham P, McKenzie M, Morris WJ, Rheaume DE, Syndikus I. Pion conformal radiation of prostate cancer: Results of a randomized study. *Int J Radiat Oncol Biol Phys* 1999 (Jan);43(1):47-55.
13. Truant T, McKenzie MR. Discussing complementary therapies: There's more than efficacy to consider (editorial). *Can Med Ass J* 1999 (Feb);160(3):351-352.
14. McKenzie M, MacLennan I, Kostashuk E, Bainbridge T: Post-irradiation sarcoma after external beam radiation therapy for localized adenocarcinoma of the prostate: Report of three cases. *Urology* 1999 (Jun);53(6):1228.
15. Clark BG, McKenzie MR: Radiation techniques for the 21st Century. *Can Med Ass J* 1999 (Nov);161(10):1292.
16. Quirt I, Robeson C, Lau CY, Kovacs M, Burdette-Radoux S, Dolan S, Tang SC, McKenzie M, Couture F: Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy. *J Clin Oncol* 2001 (Nov);19(21):4126-4134.
17. Pickles T, Agranovich A, Berthelet E, Duncan GG, Keyes M, Kwan W, McKenzie MR, Morris WJ: Testosterone recovery following prolonged adjuvant androgen ablation for prostate carcinoma. *Cancer* 2002 (Jan);94(2):362-367.

18. Sidhu S, Morris WJ, Spadinger I, Keyes M, Hilts M, Harrison R, Otto K, McKenzie M, Agranovich A: Prostate brachytherapy postimplant dosimetry: A comparison of prostate quadrants. *Int J Radiat Oncol Biol Phys* 2002 (Feb);52(2):544-552.
19. Quirt I, Robeson C, Lau, CY, Kovacs M, Burdette-Radoux S, Dolan S, Tang SC, McKenzie M, Couture F: Epoetin alfa in patients not on chemotherapy – Canadian data. *Semin Oncol* 2002 Jun;29(3 Suppl 8):75-80.
20. Wright JR, McKenzie M, DeAngelis C, Foroudi F, Paul N, Rajaraman M, Wong F, Wong R, Wong KS: Radiation induced mucositis: Co-ordinating a research agenda. *Clin Oncol (Royal Coll Rad)* 2003 Dec;15(8)473-477.
21. Liu M, Pickles T, Agranovich A, Berthelet, Duncan G, Keyes M, Kwan W, McKenzie M, Morris J, Pai H, Tyldesley S, Wu J: Impact of neoadjuvant androgen ablation and other factor on late toxicity after external beam prostate radiotherapy. *Int J Radiat Oncol Biol Phys* 2004 Jan;58(1):59-67.
22. Chung HT, Ma R, Toyota, Clark B, Robar J, McKenzie M. Audiologic and treatment outcomes following linear accelerator-based stereotactic irradiation for acoustic neuroma. *Int J Rad Oncol Biol Phys* 2004 July;59(4):1116-1121.
23. Liu M, Pickles T, Berthelet E, Agranovich A, Kwan W, Tyldesley S, McKenzie M, Keyes M, Morris J, Pai. Urinary incontinence in prostate cancer patients treated with external beam radiotherapy. *Radiother Oncol* 2005 Feb;74(2):197-201.
24. Keyes M, Schellenberg, D, Moravan V, McKenzie M, Agranovich A, Pickles T, Wu J, Liu M, Bucci J, Morris J. Decline in urinary retention incidence in 805 patients after prostate brachytherapy: The effect of learning curve? 2006 Feb;64(3):825-834.
25. Tyldesley S, Voduc D, McKenzie M, Duncan G, Liu M, Wu D. Surveillance of Stage I Testicular Seminoma: The British Columbia Cancer Agency Experience 1992 to 2002. *Urology* 2006 March;67(3):594-598.
26. Wong RKS, Paul N, Ding K, Whitehead M, Brundage M, Fyles A, Wilke D, Nabid A, Fortin A, Wilson D, McKenzie M, Ackerman, I, Souhami L, Chabot P, Pater J. 5-Hydroxytryptamine-3 receptor antagonist with or without short-course dexamethasone in the prophylaxis of radiation-induced emesis: A placebo-controlled randomized trial of the National Cancer Institute of Canada Clinical Trials Group (SC.19). *J Clin Oncol* 2006 Jul;24(21):3458-3464.
27. Candish C, McKenzie M, Clark BG, Ma R, Lee R, Vollans E, Robar J, Gete E, Martin M. Stereotactic fractionated radiotherapy for the treatment of benign meningiomas. *Int Radiat Oncol Biol Phys* 2006;4 (Supp):S3-S6.
28. Clark B, McKenzie M, Robar J, Vollans E, Candish C, Toyota B, Lee A, Ma R, Goddard K, Erridge S. Does intensity modulation improve healthy tissue sparing in stereotactic radiosurgery of complex arteriovenous malformation? *Med Dosim* 2007;32(3):172-180.
29. Thomas C, Di Maio S, Ma R, Vollans E, Chu, C, Clark B, Lee R, McKenzie M, Martin M, Toyota B. Hearing preservation following stereotactic fractionated radiotherapy for vestibular schwannomas: Prognostic implications of cochlear dose. *J Neurosurg* 2007 Nov;107(4):918-926.
30. Olson R, Chhabanai T, McKenzie M. Feasibility study of the Montreal Cognitive Assessment (MoCA) in patients with brain metastases. *Supp Care Cancer* 2008 Nov;16(11):1273-1278.
31. Palma D, Vollans E, James K, Nakano S, Moiseenko V, Shaffer R, McKenzie M, Morris J, Otto K. Volumetric Modulated Arc Therapy (VMAT) for delivery of prostate radiotherapy: comparison with Intensity Modulated Radiotherapy (IMRT) and 3-Dimensional Conformal Radiotherapy (3D-CRT). *Int J Radiat Oncol Biol Phys* 2008 Nov;72(4):996-1001.
32. Oliffe JL, Halpin M, Bottorff JL, Hislop TG, McKenzie M, Mroz L. How prostate cancer support groups do and do not survive: British Columbian Perspectives. *Am J Men's Health* 2008 June;2(2):143-155.
33. Clark B, Candish C, Vollans E, Gete E, Lee R, Martin M, Ma R, McKenzie M. Optimization of stereotactic radiotherapy treatment delivery technique for base-of-skull meningiomas. *Med Dosim* 2008; 33(3):239-247.

34. Keyes M, Miller S, Moravan V, Pickles T, McKenzie M, Pai H, Liu M, Kwan W, Agranovich A, Spadinger I, Lapointe V, Halperin R, Morris WJ. Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: Outcomes of 712 men. *Int J Radiat Oncol Biol Phys*. 2009 Mar 15;73(4):1023-32.
35. Morris WJ, Keyes M, Palma D, McKenzie MR, Spadinger I, Agranovich A, Pickles T, Liu M, Kwan W, Wu J, Lapointe V, Berthelet E, Pai H, Harrison R, Kwa W, Bucci J, Racz V, and Woods, R. Evaluation of Dosimetric Parameters and Disease Response in 1006 consecutive patients treated with 125 Iodine transperineal brachytherapy for low- and intermediate-risk prostate cancer. *Int J Radiat Oncol Biol Phys* 2009 April;73(5):1432-1438.
36. Morris WJ, Keyes M, Palma D, Spadinger I, McKenzie MR, Agranovich A, Pickles T, Liu M, Kwan W, Wu J, Berthelet E, Pai H. A population based study of biochemical and survival outcomes following permanent 125 Iodine brachytherapy for low- and intermediate-risk prostate cancer. *Urology* 2009 Apr;73(4):860-865.
37. Pugh TJ, Keyes M, Barclay L, Delaney A, Krzywinski M, Thomas D, Yang C, Agranovich A, McKenzie M, Morris WJ, Pickles T, Marra MA, Moore RA. Sequence variant discovery in DNA repair genes from radiosensitive and radiotolerant prostate brachytherapy patients. *Clin Cancer Res* 2009 August; 15(15):5008-5016.
38. Shaffer R, Nichol AM, Vollans E, Fong M, Nakano S, Moiseenko V, Schmuland M, Ma R, McKenzie M, Otto K. A comparison of volumetric modulated arc therapy (VMAT) and conventional intensity modulated radiotherapy (IMRT) for frontal and temporal high-grade gliomas. *Int J Radiat Oncol Biol Phys* 2010 March;76(4):1177-1184.
39. Olson R, Parkinson M, McKenzie M. Selection Bias Introduced by Neuropsychological Assessments. *Can J Neurosciences* 2010 March;37(2):264-268.
40. Roberge D, Menard C, Bauman G, Chan, A, Mulroy L, Sahgal A, Malone S, McKenzie M, Schroeder G, Fortin M-A, Ebacher A, Milosevic M. Radiosurgery scope of practice in Canada: A report of the Canadian Association of Radiation Oncology (CARO) Advisory Committee. *Radiother Oncol* 2010 April;95(1):122-128.
41. Olson R, Tyldesley S, Carolan H, Parkinson M, Chhanabhai T, McKenzie M. Prospective comparison of the prognostic utility of the Mini Mental State Examination and the Montreal Cognitive Assessment in patients with brain metastases. *Support Care Cancer* 2011;19(11):1849-1855.
42. Oliffe JL, Bottorff JL, McKenzie MR, Hislop TG, , Gerbrandt JS, Oglov V. Prostate cancer support groups, health literacy and consumerism: Are community-based volunteers re-defining men's health promotion? *Health (London)*. 2010 Dec 22. [Epub ahead of print]
43. Herbert C, Morris WJ, Hamm J, Lapointe V, McKenzie M, Pickles T, Spadinger I, Keyes M. The effect of loose vs. stranded seeds on biochemical no evidence of disease in patients with carcinoma of the prostate treated with iodine-125 brachytherapy. *Brachytherapy*. 2011 Nov-Dec;10(6):442-448.
44. Olson RA, Iverson GL, Carolan H, Parkinson M, Brooks BL, McKenzie M. Prospective comparison of two cognitive screening tests: diagnostic accuracy and correlation with community integration and quality of life. *J Neurooncol*. 2011;105(2):337-344..
45. Herbert C, Moiseenko V, McKenzie M, Redekop, Hsu F, Gete E, Gill, Lee R, Luchka K, Lee A, Haw C, Toyota B, Martin M. Factors predictive of obliteration after arteriovenous malformation radiosurgery. *Can J Neurosciences* 2011 Nov;38(11):845-850.
46. Herbert C, Moiseenko V, McKenzie M, Redekop G, Hsu F, Gete E, Gill B, Lee R, Luchka K, Haw C, Lee A, Toyota B, Martin M. Factors predictive of symptomatic radiation injury after linear accelerator-based stereotactic radiosurgery for intracerebral arteriovenous malformations. *Int J Radiat Oncol Biol Phys* 2012; 83(3):872-877.
47. Keyes M, Spadinger I, Liu M, Pickles T, Pai H, Hayden A, Moravan V, Halperin R, McKenzie M, Kwan W, Agranovic A, Lapointe V, Morris WJ. Rectal toxicity and rectal dosimetry in low-dose-rate iodine-125 permanent prostate implants: A long-term study in 1006 patients. *Brachytherapy*. 2012 May-Jun;11(3):199-208.

48. Herbert C, Morris WJ, Keyes M, Hamm J, Lapointe V, McKenzie M, Pickles T, Spadinger I. Outcomes following iodine-125 brachytherapy in patients with Gleason 7, intermediate risk prostate cancer: a population-based cohort study. *Radiother Oncol* 2012 May;103(2):228-32.
49. Morris J, Keyes M, Spadinger I, Kwan W, Liu M, McKenzie M, Pai H, Pickles T, Tyldesley S. Population-based, 10 year oncologic outcomes after low dose rate brachytherapy monotherapy for low and intermediate risk prostate cancer. *Cancer* 2012 Dec (epub ahead of print).
50. Hsu F, Kouhestani P, Nguyen S, Cheung A, McKenzie M, Ma R, Toyota B, Nichol A. Population-based outcomes of boost versus salvage radiosurgery for brain metastases after whole brain radiotherapy. *Radiother Oncol* 2013 Jul; 108(1):128-131.
51. Kim JO, Ma R, Akagami R, McKenzie M, Johnson M, Gete E, Nichol A. Long-term outcomes of fractionated stereotactic radiation therapy for pituitary adenomas at the BC Cancer Agency. *International Journal of Radiation Oncology, Biology, Physics* 2013 Nov;87(3):528-533.
52. Lo AC, Morris WJ, Lapointe V, Hamm J, Keyes M, Pickles T, McKenzie M, Spadinger I. Prostate-specific antigen at 4 to 5 years after low-dose-rate prostate Brachytherapy is a strong predictor of disease-free survival. *Int J Radiat Oncol Biol Phys* 2014 Jan;88(1):87-93.
53. Morris WJ, Spadinger I, Keyes M, Hamm J, McKenzie M. Whole prostate D90 and V100: A dose-response analysis of 2000 consecutive 125I monotherapy cases. *Brachytherapy* 2014 Jan-Feb;13(1):32-41.
54. Chan EK, Keyes M, Pickles T, Lapointe V, Spadinger I, McKenzie M, Morris WJ. Decline in acute urinary toxicity: A long-term study in 2011 patients with prostate Brachytherapy within a provincial institution. *Brachytherapy* 2014 Jan-Feb;13(1):46-52.
55. Morris WJ, Pickles T, Keyes M, McKenzie M, Spadinger I. Pride or prejudice: Does Phoenix flatter radiation therapy? *Brachytherapy* 2014 May-Jun;13(3):299-303.
56. Sonier M, Gete E, Herbert C, McKenzie M, Murphy J, Mooisenko V. Intensity-modulated stereotactic radiosurgery for arteriovenous malformations: guidance for treatment planning. *Radiat Oncol* 2014;9:73.
57. Garrett BM, Oliffe JL, Bottorff JL, McKenzie M, Han CS, Ogrodniczuk JS. The value of prostate cancer support groups: A pilot study of primary physicians' perspectives. *BMC Fam Pract* 2014 Mar;15(56).
58. Ye AY, Conway J, Peacock M, Clarkson PW, Lee CHL, Simmons C, Weir L, McKenzie M. Secondary sarcoma of bone post-prostate brachytherapy: A case report. *Can Urol Ass J* 2014 May;8(5-6):163-172..
59. Keyes M, Miller S, Pickles T, Halperin R, Kwan W, Lapointe V, McKenzie M, Spadinger I, Pai H, Chan EK, Morris WJ. Late urinary side effects 10 years after low-dose-rate prostate brachytherapy: Population-based results from a multiphysician practice treating with a standardized protocol and uniform dosimetric goals. *Int J Radiat Oncol Biol Phys* 2014 Nov;90(3):570-578.
60. Hamilton, SN, Tyldesley S, Hamm J, Jiang WN, Keyes M, Pickles T, Lapointe V, Kahnamelli, McKenzie M, Miller S, Morris WJ. Incidence of second malignancies in prostate cancer patients treated with low-dose-rate brachytherapy and radical prostatectomy. *Int J Radiat Oncol Biol Phys* 2014 Nov;90(4):934-941.
61. Lefresne S, Berthelet E, Cashman R, Levy K, Carolan H, McKenzie M, Kostuik P, Olson R. The Vancouver Rapid Access Clinic for palliative lung radiation: Providing more than just rapid access. *Supp Care Cancer* 2015 Jan;23(1):125-132.
62. Oliffe JL, Chambers S, Barrett B, Bottorff JL, McKenzie M, Han CS, Ogrodniczuk JS. Prostate cancer support groups: Canada-based specialists' perspectives. *Am J Men's Health* 2015 Mar;9(2):163-172.

63. Lo A, Pickles T, Keyes M, McKenzie M, Tyldesley S, Morris J. Patterns of Recurrence after Low-Dose-Rate Prostate Brachytherapy: A population-based study of 2223 consecutive low- and intermediate-risk patients. *Int J Radiat Oncol Biol Phys* 2015 March;91(4):745-751.
64. Keyes M, Pickles T, Crook J, McKenzie M, Cheung A, Spadinger I, LaPointe V, Bachand WF, Morris J. Effect of aging and long-term erectile function after Iodine-125 prostate brachytherapy. *Brachytherapy* published on-line 13-Feb-2015.
65. Mason M, Parulekar W, Sydes M, Brundage M, Kirkbride P, Gospodarowicz M, Cowan R, Kostashuk E, Anderson J, Swanson G, Parmar M, Hayter C, Jovic G, Hiltz A, Hetherington J, Sathya J, Barber J, McKenzie M, El-Sharkawi S, Souhami L, Hardman PDJ, Chen B, Warde P. Final report of the intergroup randomized study of combined androgen deprivation therapy plus radiotherapy versus androgen deprivation therapy alone in locally advanced prostate cancer. *J Clin Oncol* 2015 Jul;33(19):2143-2150.
66. Hsu F, Nichol A, Ma R, Kouhestani P, Toyota B, McKenzie M. Stereotactic radiosurgery for metastases in eloquent central brain locations. *Can J Neurosciences* 2015 Sep;42(5):333-337..
67. Nichol A, Ma R, McKenzie M, Carolan H, Olson R, Schellenberg D, Hsu F, Germain F, Cheung A. Volumetric radiosurgery for one to ten brain metastases: A multi-center, single-arm, phase 2 study. Submitted to *Int J Radiat Oncol Biol Phys* 2016 Feb;94(2):312-321.
68. Howard M, Bonham AJ, Heyland DK, Sudore R, Fassbender, K, Robinson CA, McKenzie M, Elston D, You JJ. Measuring engagement in advance care planning: A multicentre feasibility study. *BMJ Open* 2016;6:e010375.
69. Hamilton SN, Nichol AM, Truong P, McKenzie M, Hsu FHC, Cheung A, Dolman P, Gete E, Ma RMK. Visual outcomes and local control after fractionated stereotactic radiation therapy for optic nerve sheath meningioma. *Ophthalm Plast Reconstruct Surg* published on-line 20-Apr-2017.
70. Robinson CA, Fyles G, McKenzie M. Oncologist experience implementing goals of care discussions in everyday ambulatory oncology practice: Implications for education. *J Cancer Educ* 2017 Jun;32(2):301-307.
71. Morris J, Tyldesley S, McKenzie M, Duncan G, Pai H, Murray N, Hamm J, Morton G, Halperin R. Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An analysis of survival endpoints for a randomized trial comparing low-dose rate brachytherapy boost to a dose escalated external beam boost for high- and intermediate-risk prostate cancer. *Int J Radiat Oncol Biol Phys* 2017 Jun;98(2):275-285.
72. Rodda S, Tyldesley S, Morris WJ, Keyes M, Halperin R, Pai H, McKenzie M, Duncan G, Morton G, Hamm J, Murray N. ASCENDE-RT: An analysis of treatment-related morbidity for a randomized trial comparing a low-dose-rate brachytherapy boost with a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. *Int J Radiat Oncol Biol Phys* 2017 Jun;98(2):286-295.
73. Lefresne S, Olson R, Cashman R, Kostuik P, Jang W-N, Levy K, McKenzie M, Hulstyn A, Liu M, Wu J, Berthelet, E. Prospective analysis of patient reported symptoms and quality of life in patients with incurable lung cancer treated in a rapid access clinic. *Lung Cancer* 2017 Oct;112:35-40.
74. Tetreault-Laflamme A, Crook J, Hamm J, Pickles T, Keyes M, McKenzie M, Pai H, Bachand F, Morris. Long term PSA stability and predictive factors of failure after permanent seed brachytherapy. *J Urol* August 2017 epub.
75. Parimi S, Tsang E, Alexander A, McKenzie M, Bachand F, Sunderland K, Chi KN, Aparicio M, Worsley D, Tyldesley S. A population-based study of the use of radium 223 in metastatic castration-resistant prostate cancer: Factors associated with treatment completion. *Can Urol Ass J* 2017 Oct;11(10):350-355.
76. Lo A, Ayre G, Ma R, Hsu F, Akagami R, McKenzie M, Valev B, Gete E, Vallieres I, Nichol A. A population-based study of stereotactic radiosurgery of fractionated stereotactic radiotherapy for vestibular schwannoma: Long-term outcomes and toxicities. *Int J Rad Onc Biol Phys* 2018 Feb;100(2):443-451.

77. Howard F, Goddard K, Tran J, Aparicio A, Lo A, Ullett A, McKenzie M, Goddard K. Documentation of late-effects risks and screening recommendations for adolescent and young adult central nervous system, soft tissue or bone tumor survivors treated with radiotherapy in British Columbia Canada. *J Adolesc Young Adult Oncol* (in press).
78. Wiggermann V, Lapointe E, Litvin L, Graf C, Hernandez-Torres E, McKenzie M, Vavasour IM, Laule C, MacMillan EL, Li DKB, Kolind SH, Rauscher A, Traboulsee AL. Longitudinal advanced MRI case report of white matter radiation necrosis. *Annals Clin Translat Neurol* published on-line 2018 December <http://dx.doi.org/10.1002/acn3.704>.
79. You JJ, Allatt P, Howard M, Robinson CA, Simon J, Sudore R, Tan A, Bernard C, Swinton M, Jian X, Klein D, McKenzie M, Fyles G, Heyland DK. Short Graphic Values History Tool for decision making during serious illness. *BMJ Supp Pall Care* 2019;0:1–8. doi:10.1136/bmjspcare-2018-001698.
80. Lo A, Laperriere N, Hodgson D, Bouffet E, Nicholson J, McKenzie M, Hukin J, Cheng S, Goddard K. Canadian patterns of practice for intracranial germ cell tumors in adolescents and young adults. *J Neurooncol* (in press).
81. Parimi S, Bondy S, Tsang E, McKenzie MR, Bachand F, Aparicio, Duncan G, Sunderland K, Olson RA, Pai HH, Alexander AS, Lapointe V, Chi KN, Tyldesley S. Pain response in a population-based study of Radium-223 (Ra223) for metastatic castration-resistant prostate cancer. *Can Urol Ass J* 2019 Oct;13(10):E311-E316.
82. Rousseau E, Wilson D, Lacroix-Poisson F, Krauze A, Chi K, Gleave M, McKenzie M, Tyldesley S, Goldenberg SL, Benard F. A prospective study on 18F-DCFPyL PSMA PET/CT imaging in biochemical recurrence of prostate cancer. *J Nucl Med* published on-line 12-Apr-2019.
83. Oh J, Dennis K, Lefresne S, Livergant J, McKenzie M. End-of-life discussions in practice: Survey among Canadian radiation oncologists. *Ann Pall Med* published on-line 25-Jun-2019.
84. Loewen SK, Halperin R, Perry G, McKenzie M, Vigneault E, Stuckless T, Brundage. Employment outcomes for recent Canadian radiation oncology graduates. *Curr Oncol* 2019 Sep;26(4):e510-e514.